Nama's AI scorecard currently rates Supernus Pharmaceuticals Hold (5.2 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is SUPN's P/E ratio?

Supernus Pharmaceuticals trades at a trailing price-to-earnings ratio of 10.5.

When does SUPN report earnings?

Supernus Pharmaceuticals's next scheduled report is on Feb 25, 2027. Analysts expect EPS of $1.22.

What is the SUPN price target?

The median analyst price target from 6 analysts is $50.00, with a range of $45.00 – $87.00.

Is SUPN Shariah compliant?

Nama's AAOIFI-style screen reads Supernus Pharmaceuticals as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Nama Insights

Supernus Pharmaceuticals (SUPN)

Healthcare · Drug Manufacturers Specialty Generic · NASDAQ

Supernus Pharmaceuticals (SUPN) is a Healthcare company in the Drug Manufacturers Specialty Generic industry. It has a market capitalization of $1.52B, a trailing price-to-earnings ratio of 10.5 and a free-cash-flow yield of 3.1%. Over the most recent reported fiscal year, revenue grew 8.6% and free cash flow per share fell 73.4%. Nama's AI scorecard rates it Hold, 5.2 out of 10. On 12-month momentum it ranks in the middle band of its market.

AI scorecard

Hold · 5.2/10

The sections balance. As of Nov 7, 2026.

Momentum

Middle · +13.3% over 12 months ex. last

Middle fifth of its market on the past year's move.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-56.2%

How far the last close sits under the highest price of the past five years.

Market cap	$1.52B
Trailing P/E	10.5
Price / book	1.5
Price / sales	1.8
FCF yield	3.1%
Dividend yield	—
Gross margin	88.1%
Operating margin	-6.7%
Net margin	-13.2%
Revenue growth (YoY)	+8.6%
Revenue growth (3-yr annual)	+2.5%
EPS growth (YoY)	+10.9%
FCF/share growth (YoY)	-73.4%
Beta	0.6
Exchange	NASDAQ
Sector	Healthcare
Industry	Drug Manufacturers Specialty Generic

SUPN earnings

Next report: Feb 25, 2027 (Q4 2026, EPS estimate $1.22). Beat the EPS estimate in 3 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Oct 29, 2026	$0.88	$0.49	+79.6%	$226.77M
Q2 2026	Aug 3, 2026	$0.53	$0.51	+3.9%	$219.06M
Q1 2026	May 5, 2026	$0.21	$0.28	-25.0%	$207.71M
Q4 2025	Feb 24, 2026	$0.88	$0.28	+214.3%	$211.57M

SUPN analyst price target

Median target $50.00 from 6 analysts, ranging $45.00 – $87.00.

Drug Manufacturers Specialty Generic peers

Ticker	Company	Market cap	P/E
TAK	Takeda Pharmaceutical	$67.16B	42.0
TEVA	Teva Pharmaceutical Industries	$49.72B	18.0
HLN	Haleon	$40.17B	21.3
ZTS	Zoetis	$32.81B	12.0
UTHR	United Therapeutics	$23.94B	21.2
VTRS	Viatris	$22.87B	7.8
NBIX	Neurocrine Biosciences	$16.66B	16.5
ELAN	Elanco Animal Health	$12.86B	24.3

Explore live SUPN data on Nama Insights →

Recent Congressional trades

Supernus Pharmaceuticals trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
Gilbert Cisneros	House	Buy	$1,001 - $15,000	Apr 7, 2026
Gilbert Cisneros	House	Buy	$1,001 - $15,000	Jan 12, 2026
Gilbert Cisneros	House	Sell	$1,001 - $15,000	Nov 18, 2025
Gilbert Cisneros	House	Buy	$1,001 - $15,000	Apr 7, 2025

SUPN FAQ

Is SUPN a buy?: Nama's AI scorecard currently rates Supernus Pharmaceuticals Hold (5.2 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is SUPN's P/E ratio?: Supernus Pharmaceuticals trades at a trailing price-to-earnings ratio of 10.5.
When does SUPN report earnings?: Supernus Pharmaceuticals's next scheduled report is on Feb 25, 2027. Analysts expect EPS of $1.22.
What is the SUPN price target?: The median analyst price target from 6 analysts is $50.00, with a range of $45.00 – $87.00.
Is SUPN Shariah compliant?: Nama's AAOIFI-style screen reads Supernus Pharmaceuticals as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.